RDGL — VIVOS INC

—
OTC · Health Care · Health Care Equipment & Supplies · CIK 1449349 ·
Last close
$0.04
Market Cap
$21.07M
52W High
$0.12
52W Low
$0.04
ADV30
608,589
Next earnings
—
Vivos Inc., a radiation oncology medical device company, engages in the development of yttrium-90-based precision radionuclide therapy devices for the treatment of non-resectable tumors in the United States. The company develops RadioGel, which is an injectable particle-gel for Precision Radionuclide Therapy radiation treatment of cancerous tumors in people and animals; and IsoPet for the treatment of solid tumors in animals. It is also developing PLGA-g-PEG polymers; PrecisionGel, a hydrogel polymer platform for delivering active pharmaceutical ingredients and therapeutic agents; Duncan Chiller, a general laboratory equipment for non-water localized chilling; and other products under the Alpha-Gel, Beta-Gel, Gamma-Gel, and Peltier Chiller brands. The company was formerly known as Advanced Medical Isotope Corporation and changed its name to Vivos Inc. in December 2017. Vivos Inc. was incorporated in 1994 and is headquartered in Kennewick, Washington.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 28,900 21,462 -748,838 -731,594 2,284,340 1,807,350 221,600
Jun 2026 36,400 -1,720 -654,529 -830,189 2,879,570 2,336,022 123,955
Mar 2026 36,068 -8,018 -545,492 -1,184,845 2,950,505 2,525,782 253,195
Dec 2025 24,752 -3,105 -1,095,719 -1,078,514 1,867,583 1,558,525 206,743

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-2,167,476
Investing CF
$-245,744
Financing CF
$2,191,837
CapEx
$-245,744
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$0.00
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-90,442,280
Inventory
$56,427
Receivables
$15,650
ST Investments
—
EBIT TTM
$-2,806,423
Pretax Income TTM
$-3,600,842
Interest Exp TTM
$196,000
Analysts
—

Yahoo Snapshot (yfinance, live)

Total Revenue
$99,099
EBITDA
—
Free Cash Flow
$-1,544,673
Enterprise Value
$31,625,180
Total Cash
$2,336,022
Total Debt
$103,153
Shares Out
513,788,110
Trailing EPS
$-0.01
Book Value
$-0.02
ROE
-132.5%
ROA
-62.5%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 68,379 -3,165,047 -3,066,017 1,867,583 206,743 1,660,840 -2,057,743
Dec 2024 27,995 -2,604,384 -2,910,448 2,233,456 86,209 2,147,247 -1,684,039
Dec 2023 19,500 -2,793,146 -2,894,753 1,610,124 245,004 1,365,120 -1,293,023
Dec 2022 36,499 -2,517,749 -2,470,161 1,742,736 81,692 1,661,044 -1,120,058

TTM Snapshot

Revenues TTM
$99,099
NetIncome TTM
$-3,600,842
OpCashFlow TTM
—
Assets (Latest)
$2,879,570
Forward EPS
—

Peers — same industry

TickerNameMarket CapLastDaily %
BEAT HeartBeam, Inc. $21.13M $0.33 —
NNOX Nano-X Imaging Ltd. $22.59M $0.29 —
ITOC iTonic Holdings Ltd $18.39M $1.96 —
FOFA FAMILY OFFICE OF AMERICA, INC. $24.66M $0.80 —
QTI QT IMAGING HOLDINGS, INC. $24.83M $1.69 —

News headlines (Yahoo Finance, 1h cache)

How Is Vivos Expanding Its IsoPet Cancer Treatment Network With Four New US Veterinary Clinics?
2026-11-03 16:16 · Yahoo
Vivos Inc. Announces Expansion of IsoPet® Animal Cancer Division with Four New Veterinary Clinics Across the United States
2026-11-03 13:30 · Yahoo
CORRECTION: SOD Sciences Welcomes Vivos Therapeutics as Strategic Investor and Partner in the ReBalU Primed Cell Test
2026-10-29 14:52 · Yahoo
SOD Sciences Welcomes Vivos Therapeutics as Strategic Investor and Partner in the ReBalU Primed Cell Test
2026-10-20 15:40 · Yahoo
Vivos Therapeutics Closes Acquisition of Stake in SOD Sciences and 50% Interest in Pseudohypoxia Test, Opening a Potential Path to Access More Than 325,000 New Patients Through the AHA Channel
2026-10-19 21:01 · Yahoo
Vivos Inc. Peer-Reviewed PrecisionGel Publication Strengthens Scientific Case for Drug Delivery Platform
2026-09-03 13:59 · Yahoo
Vivos Therapeutics and South Palm Cardiovascular Associates Sign Definitive Agreements to Launch Regional Sleep Testing and Treatment Center
2026-08-28 12:45 · Yahoo
Vivos Begins IsoPet Shipments and Secures India Manufacturing Authorization
2026-08-18 14:47 · Yahoo
Vivos Inc. Achieves Two Major Operational Milestones: First IsoPet® Shipments from New U.S. Production Facility and Authorization from India’s Nuclear Regulatory Authority for International Manufactur
2026-08-18 12:30 · Yahoo
Vivos Therapeutics Schedules Release of Second Quarter 2026 Financial Results and Conference Call
2026-08-14 12:45 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.